Advertisement

Uncategorized

The FDA has approved a risk evaluation and mitigation strategy for Cephalon's Fentora and Actiq drugs to manage breakthrough pain in opioid-tolerant patients with cancer, according to a Cephalon news release.

Advertisement
Advertisement